Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents
European Journal of Cancer2020Vol. 136, pp. 116–129
Citations Over TimeTop 10% of 2020 papers
Andrew D.J. Pearson, C. Michel Zwaan, E. Anders Kolb, Dominik Karres, Julie Guillot, Su Young Kim, Lynley V. Marshall, Sarah K. Tasian, Malcolm A. Smith, Todd M. Cooper, Peter C. Adamson, Elly Barry, Bouchra Benettaib, Florence Binlich, Anne Borgman, Erica Brivio, Renaud Capdeville, David Delgado, Douglas V. Faller, Linda Fogelstrand, Paula G. Fraenkel, Henrik Hasle, Delphine Heenen, Gertjan J.L. Kaspers, Mark W. Kieran, Jan‐Henning Klusmann, Giovanni Lesa, Franca Ligas, Silvia Mappa, Hesham Mohamed, Andrew S. Moore, Joan Morris, Kerri Nottage, Dirk Reinhardt, Nicole Scobie, Stephen J. Simko, Thomas Winkler, Koen Norga, Gregory H. Reaman, Gilles Vassal
Abstract
These initiatives continue to accelerate drug development for children with AML and ultimately improve clinical outcomes.
Related Papers
- → Development of CNS leukaemia in acute myeloid leukaemia in childhood.(1976)18 cited
- → The Mozart effect in chronic myeloid leukaemia(2024)
- → Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey(2019)
- → Co-existence of Untreated Chronic Lymphocytic Leukaemia and Acute Myeloid Leukaemia: A Rare Case of Synchronous Dual Haematological Malignancy(2025)